Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan Earthquake and the Fukushima Daiichi nuclear disaster. Fourteen years later ...

Mark Zuckerberg is now the proud owner of a t-shirt actually worn by Jesse Eisenberg in “The Social Network.” On a recent episode of “The Colin & Samir Show,” Zuckerberg wore a t-shirt ...

Casual hanging-out-at-home staples get a boost from bold accessories and pops of red. In Fashion From left: Nili Lotan jeans, $395, nililotan.com; Celine by Hedi Slimane shoes, $1,150, celine.com ...

Japanese drugmaker Daiichi Sankyo’s (TYO:4568) Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 ...